


PHARMACEUTICAL 2020

Orgenesis Inc. Rank 129 of 362







PHARMACEUTICAL 2020

Orgenesis Inc. Rank 129 of 362



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 145% points. The greatest weakness of Orgenesis Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -84%, being 219% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	25,979
Cost of Goods Sold	18,232
Intangible Assets	29,147
Liabilities, Current	31,579
Liabilities, Non-Current	23,883
Other Assets	12,915
Other Compr. Net Income	1,464
Other Expenses	2,624
Other Liabilities	0
Other Net Income	-874
Property and Equipment	24,454
Research and Development	12,458
Revenues	33,484
Selling, General and Administrative Expense	25,337

Output Variable	Value in 1000 USD
Assets	92,495
Liabilities	55,462
Expenses	58,651
Stockholders Equity	37,033
Net Income	-26,041
Comprehensive Net Income	-25,309
Economic Capital Ratio	-84%